Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Universal CAR-T therapy produces CRs in relapsed/refractory T-ALL

Publish date:: May 19, 2020

Key clinical point: The universal chimeric antigen receptor T-cell therapy TruUCAR GC027 has produced responses in adults with relapsed/refractory T-cell acute lymphoblastic leukemia.

Major finding: Initally, 100% of patients achieved complete remission (CR) or CR with incomplete count recovery. At 1 month, 80% of patients had a CR and were minimal residual disease negative.

Study details: A phase 1 study of 5 patients.

Disclosures: Dr. Wang is an employee of Gracell Biotechnologies, the company developing TruUCAR GC027.

Citation:

Wang X et al. AACR 2020, Abstract CT052.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in ALL

In high-risk first relapse ALL, blinatumomab seen superior to consolidation chemo,

Well tolerated with promising responses in ALL/LL: Venetoclax plus navitoclax plus chemotherapy,

Highly effective in Ph-negative B-cell ALL: Hyper-CVAD with sequential blinatumomab,

COVID-19–related outcomes poor for patients with hematologic disease in ASH registry,

Study: Complications from childhood ALL and its treatment are common, but can be managed,